MDxHealth SA Stock Euronext Bruxelles
Stocks
MDXH
BE0974461940
Biotechnology & Medical Research
| Market Cap | 59.29M 68.72M 55.85M 50.88M 95.11M 6.49B 95.82M 661M 257M 3.32B 258M 252M 10.9B | P/E 2026 * |
-1.4x | P/E 2027 * | -2.53x |
|---|---|---|---|---|---|
| Enterprise Value | 180M 209M 170M 155M 289M 19.71B 291M 2.01B 779M 10.08B 784M 766M 33.11B | EV / Sales 2026 * |
1.87x | EV / Sales 2027 * | 1.82x |
| Free-Float |
77.86% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : MDxHealth SA
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 18/02/2019 | |
Ron Kalfus
DFI | Director of Finance/CFO | 52 | 22/07/2019 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Hilde Windels
BRD | Director/Board Member | 61 | 01/11/2017 |
Koen Hoffman
CHM | Chairman | 58 | 01/01/2018 |
| Director/Board Member | 64 | 18/02/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.58% | - | - | 68.73M | |
| +0.97% | -1.75% | +2.17% | +18.46% | 49.74B | |
| -0.30% | -1.02% | +451.04% | +496.95% | 44.98B | |
| +2.13% | +1.70% | +38.27% | +17.61% | 42.52B | |
| +0.87% | -3.88% | +18.21% | +73.17% | 40.78B | |
| -0.90% | -1.74% | +15.20% | +48.44% | 32.89B | |
| +2.71% | +5.66% | - | - | 17.09B | |
| +1.68% | -3.43% | +24.71% | +116.83% | 16.28B | |
| +1.70% | -1.75% | +12.00% | +28.50% | 14.4B | |
| +3.34% | -1.98% | +78.65% | +39.19% | 13.48B | |
| Average | +1.22% | -2.42% | +80.03% | +104.89% | 30.24B | |
| Weighted average by Cap. | +1.01% | -2.25% | +97.63% | +123.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 96.12M 111M 90.55M 82.5M 154M 10.53B 155M 1.07B 416M 5.38B 418M 409M 17.68B | 109M 126M 103M 93.41M 175M 11.92B 176M 1.21B 471M 6.09B 474M 463M 20.01B |
| Net income | -29.64M -34.36M -27.92M -25.44M -47.55M -3.25B -47.91M -331M -128M -1.66B -129M -126M -5.45B | -18.12M -21M -17.07M -15.55M -29.07M -1.98B -29.29M -202M -78.43M -1.01B -78.87M -77.15M -3.33B |
| Net Debt | 121M 140M 114M 104M 194M 13.22B 195M 1.35B 523M 6.76B 526M 514M 22.21B | 139M 161M 131M 119M 222M 15.19B 224M 1.55B 600M 7.76B 604M 590M 25.51B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
